A BSTRACT Objective: This study evaluated the impact of structured clinical pharmacist-led counseling on hospital admissions due to chemotherapy side effects, patient satisfaction, and cost avoidance in patients receiving intravenous chemotherapy. Methods: A prospective pre–post quality improvement study was conducted at a tertiary care center in Saudi Arabia. The preintervention cohort (October 2024–February 2025, n = 118) received standard care; the postintervention cohort (April–August 2025, n = 135) received structured 30-min pharmacist-led counseling covering regimen-specific education, anticipatory guidance on toxicity, self-management strategies, red-flag symptom recognition, and monitoring protocols. The primary outcome was the hospital admission rate due to chemotherapy-related side effects. Secondary outcomes included side effect-specific admissions, patient satisfaction, and economic impact. Findings: The intervention achieved a 34.4% relative reduction in admission rates (13.56%–8.89%; P = 0.02; number needed to treat = 22). Complete elimination of admissions for gastrointestinal toxicities and 38.8% reduction in febrile neutropenia admissions were observed. Patient satisfaction reached 94.4%, with 97.2% service coverage. Net cost savings totaled $38,850 over 5 months (ROI: 747%), with febrile neutropenia prevention accounting for 76.6% of savings. Conclusion: Structured pharmacist-led counseling significantly reduced chemotherapy-related hospital admissions, achieved exceptional patient satisfaction, and demonstrated strong economic value, supporting its integration as standard supportive care in oncology practice.
No takes yet. Share an insight, caveat, or question.
Assiri et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: